Back

Cannabis use prevalence before and early after partial legalisation in Germany

Kotz, D.; Manthey, J.; Klosterhalfen, S.; Steinhoff, P.; Viechtbauer, W.

2026-03-19 epidemiology
10.64898/2026.03.18.26348683 medRxiv
Show abstract

Background and AimsOn April 1st, 2024, Germany implemented the Act on the Handling of Cannabis for Non-Medical Use (KCanG), allowing adults to cultivate and possess recreational cannabis. We assessed whether this policy shift was associated with a change in the prevalence of cannabis use in the general population and in daily or almost daily cannabis use. DesignA series of 21 repeated cross-sectional surveys conducted between April/May 2022 and October/November 2025 (covering the period approximately two years before and one and a half years after the KCanG). SettingPopulation of Germany. ParticipantsA total of 32,991 people aged 14-64 years, including 2,092 (6.3%) people who used cannabis in the past 12 months. MeasurementsPast 12-month cannabis use (at least once). In past 12-month users: daily or almost daily use. To test a potential change in prevalence following the KCanG, we used piecewise binomial logistic regression models using the exact date of each wave as the predictor variable, allowing for a change in the slope at the first full wave after implementation of the KCanG in April 2024, with a random effect for wave. We conducted this analysis for the total sample as well as stratified by gender (male vs. female), age (14-24 vs. 25-64 years), and for daily or almost daily cannabis use in the subgroup of people who used cannabis in the past 12 months. Sensitivity analyses used alternate intervention dates (in-time placebo tests). FindingsThe prevalence of cannabis use and the share of (almost) daily users among 12-month users remained largely stable before and after the law reform. None of the slope coefficients before the introduction of the KCanG were statistically significant (all p [≥] .08), and none of the coefficients for the change in the slope were statistically significant (all p [≥] .31). Results of sensitivity analyses confirmed the stable trends for both outcomes. ConclusionsThe legislation of cannabis introduced in Germany in April 2024 was not associated with a change in trends of 12-month cannabis use prevalence early (1.5 years) after implementation, and also not with a change in the proportion of heavy users among past-12-month users. We recommend continued close monitoring of trends using multiple data sources and over a longer post-implementation period, as the effects of the legislation may not have fully unfolded yet.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Addiction
25 papers in training set
Top 0.1%
17.4%
2
Drug and Alcohol Dependence
37 papers in training set
Top 0.1%
14.2%
3
BMC Medicine
163 papers in training set
Top 0.6%
6.3%
4
Nature Human Behaviour
85 papers in training set
Top 0.7%
4.1%
5
International Journal of Drug Policy
11 papers in training set
Top 0.1%
3.9%
6
PLOS ONE
4510 papers in training set
Top 36%
3.9%
7
PLOS Medicine
98 papers in training set
Top 1%
3.6%
50% of probability mass above
8
The British Journal of Psychiatry
21 papers in training set
Top 0.2%
3.6%
9
BMJ Open
554 papers in training set
Top 6%
3.6%
10
JAMA Network Open
127 papers in training set
Top 1%
2.7%
11
JAMA Psychiatry
13 papers in training set
Top 0.2%
2.6%
12
Psychological Medicine
74 papers in training set
Top 0.8%
2.3%
13
BMC Public Health
147 papers in training set
Top 3%
1.7%
14
Scientific Reports
3102 papers in training set
Top 62%
1.5%
15
Epidemiology and Psychiatric Sciences
10 papers in training set
Top 0.2%
1.2%
16
Preventive Medicine
11 papers in training set
Top 0.1%
1.1%
17
The Lancet Public Health
20 papers in training set
Top 0.5%
0.9%
18
Nicotine & Tobacco Research
11 papers in training set
Top 0.2%
0.9%
19
Frontiers in Public Health
140 papers in training set
Top 8%
0.8%
20
Nature Communications
4913 papers in training set
Top 61%
0.8%
21
American Journal of Psychiatry
20 papers in training set
Top 0.4%
0.8%
22
Frontiers in Pharmacology
100 papers in training set
Top 4%
0.8%
23
Frontiers in Psychiatry
83 papers in training set
Top 3%
0.7%
24
European Psychiatry
10 papers in training set
Top 0.8%
0.6%